<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000953</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 169</org_study_id>
    <secondary_id>Protocol -38/-022</secondary_id>
    <nct_id>NCT00000953</nct_id>
  </id_info>
  <brief_title>Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients</brief_title>
  <official_title>Evaluation of Brovavir ( BV-ara-U; SQ 32,756 ) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare the efficacy of oral sorivudine (brovavir) and oral acyclovir for the treatment of
      localized herpes zoster in HIV-infected patients.

      HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster
      virus ( VZV ) infections, also called shingles. Acyclovir, an approved drug, is widely used
      to treat VZV infections in the HIV population. Since no data from controlled studies are
      available to define the role of antiviral therapy for VZV infections in HIV-infected
      patients, a study is needed to test the relative efficacy of brovavir, an experimental
      antiviral drug, versus that of acyclovir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster
      virus ( VZV ) infections, also called shingles. Acyclovir, an approved drug, is widely used
      to treat VZV infections in the HIV population. Since no data from controlled studies are
      available to define the role of antiviral therapy for VZV infections in HIV-infected
      patients, a study is needed to test the relative efficacy of brovavir, an experimental
      antiviral drug, versus that of acyclovir.

      One hundred-eighty patients are randomized to receive either brovavir or acyclovir as
      follows: brovavir or its matching placebo once daily and acyclovir or its matching placebo
      five times daily. Treatment continues for 10 days. Entry into the study must occur within 72
      hours of lesion development. Patients are followed in person daily or at regular intervals
      during study drug administration and on days 14, 21, and 28, and then monthly by telephone
      for 11 months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">September 1996</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>180</enrollment>
  <condition>HIV Infections</condition>
  <condition>Chickenpox</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Medication for concurrent conditions (e.g., insulin, antihypertensives,
             bronchodilators, digoxin) or antibacterials or antifungals to treat concurrent
             infections at other sites or superinfection of the zoster lesion.

          -  Anti-inflammatory, analgesic (including narcotic analgesic), or antipyretic agents.

          -  Antidepressants and antipsychotics such as amitriptyline and/or fluphenazine.

          -  Nerve blocks.

          -  AZT, ddI, ddC, and amantadine.

          -  Low-dose corticosteroids for treatment of an underlying (not zoster-related) disease.

          -  Immune modulators without varicella-zoster virus activity (e.g., GM-CSF, gp160
             vaccine).

        Patients must have:

          -  HIV infection.

          -  Localized, cutaneous herpes zoster (shingles).

          -  Zoster-associated rash present for 3 or fewer days prior to entry.

        Prior Medication:

        Allowed:

          -  Zidovudine.

          -  ddI.

          -  ddC.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions and symptoms are excluded:

          -  Chickenpox.

          -  Evidence of visceral dissemination (organ involvement, i.e., brain, liver, or lung)
             and/or cutaneous dissemination (more than 20 vesicles in dermatomes beyond contiguous
             dermatomes) of zoster.

          -  Zoster-like lesion caused by organism other than VZV (e.g., HSV, enterovirus, or
             Mycoplasma).

          -  Bacterial superinfection of zoster lesion.

          -  Zosteriform lesion previously treated with topical antiviral agents.

          -  Acute, life-threatening opportunistic infection requiring treatment (ongoing
             suppressive or prophylactic maintenance therapy other than ganciclovir or foscarnet is
             permitted).

          -  Concurrent severe disease that may either impair ability to take oral medication in
             capsule or tablet form or limit survival during the 10-day treatment period or during
             acute phase follow-up (28 days).

          -  Suspected acute deterioration of renal or hepatic function.

          -  Mental impairment that precludes ability to comply with protocol.

          -  Any condition that would render the patient unsuitable for treatment.

        Concurrent Medication:

        Excluded during acute phase of study:

          -  Antiviral medications other than AZT, ddI, ddC, or anti-Parkinson's drugs (i.e.,
             amantadine).

          -  Interferon.

          -  Isoprinosine.

          -  Levamisole.

          -  Transfer factor.

          -  Topical virucidal agents, oxidizing agents, DMSO, cell division-stimulating/healing
             agents, or astringents.

          -  Topical anesthetics (such as capsaicin or xylocaine).

          -  Topical creams or ointments that may interfere with evaluation of zoster lesions.

          -  Cimetidine.

          -  Fluorouracil or its derivatives, flucytosine, or cyclophosphamide (during drug
             administration and for 2 weeks thereafter).

          -  High-dose corticosteroids.

          -  Anticoagulant therapy (heparin locks and low-dose warfarin sodium permitted).

          -  Probenecid or derivatives.

          -  Treatment for any acute, life-threatening opportunistic infection (suppressive or
             prophylactic maintenance therapy other than ganciclovir or foscarnet is permitted).

        Use of the following drugs is discouraged during the long-term phase of the study:

          -  Antiviral agents with VZV activity.

          -  Immunomodulators with presumed VZV activity.

          -  VZV immune globulin.

          -  Capsaicin.

          -  Cimetidine.

        Patients with the following prior conditions are excluded:

          -  History of immediate hypersensitivity or serum sickness reaction or idiosyncratic
             reaction (such as hepatic necrosis or Stevens-Johnson syndrome) to any nucleoside
             analog antiviral agent or to any anticancer therapy with cytolytic agents.

        Prior Medication:

        Excluded within 1 month prior to entry:

          -  Any investigational drugs or treatments not licensed for any indication (other than
             ddI or ddC).

        Excluded within 2 weeks prior to entry:

          -  Any systemic antiviral therapy, including ganciclovir, foscarnet, vidarabine,
             acyclovir, or ribavirin.

          -  Any antiretroviral drug other than zidovudine, ddI, and ddC.

          -  Immune globulin (e.g., IgG, VZIG).

        Excluded within 72 hours prior to entry:

          -  Cyclophosphamide.

          -  Flucytosine.

          -  Fluorouracil or its derivatives.

        Alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Crumpacker C</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Southern California / LA County USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900331079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Med Ctr</name>
      <address>
        <city>Martinez</city>
        <state>California</state>
        <zip>94553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Med Group</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Naval Hosp</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Zion Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Health Sciences Ctr</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Med Ctr / Community AIDS Program</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Hawaii / Leahi Hosp</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natl Institutes of Health / NIAID</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Gen Hosp / Harvard Med School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Deaconess Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univ</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Sloan - Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's - Roosevelt Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY / Health Sciences Ctr at Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY / Health Sciences Ctr at Syracuse</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Med Ctr</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Dermatology Associates</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univ / ACTU-Univ Clinic</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Veterans Administration Med Ctr</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med College of Ohio</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Adm Med Ctr / Rsch &amp; Education Grp</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>972109951</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Veterans Administration Med Ctr</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas, Southwestern Med Ctr of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston Med Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>775550882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX San Antonio Health Science Ctr</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>782847881</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Hosp</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Virginia Health Sciences Ctr</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research Inc</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salem Veterans Administration Med Ctr</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Hemophilia Foundation</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gnann J, et al. Sorivudine (BV-araU) versus acyclovir for Herpes zoster in HIV-infected patients. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:55</citation>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>February 25, 2011</last_update_submitted>
  <last_update_submitted_qc>February 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <keyword>Herpes Zoster</keyword>
  <keyword>Acyclovir</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>sorivudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Sorivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

